Study for the effect of SGLT2 inhibitors in high risk patients of dialysis with type 2 diabetes

Study for the effect of SGLT2 inhibitors in high risk patients of dialysis with type 2 diabetes - The effect of SGLT2 inhibitors in patients with renal dysfunction

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035263

Enrollment

Registered

2018-12-15

Start date

2018-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Continuing SGLT2 inhibitors concomitant with diet therapy for more than 2 years 2) eGFR < 60ml/min/1.73m2 at starting SGLT2 inhibitors 3) There are eGFR data for more than 2 years both before and after starting SGLT2 inhibitors

Exclusion criteria

Exclusion criteria: 1) type 1 diabetes 2) severe liver dysfunction 3) pregnancy, nursing woman or possibly pregnant woman 4) severe diabetic ketosis, diabetic coma 5) severe infection, pre and post operation , severe trauma 7) uncontrolled diet therapy 8) poor adherence for medication 9) patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Change in eGFR decline rate between before and after 2 years of SGLT2 inhibitors administration	—

Secondary

Measure	Time frame
Glycemic control Weight Blood pressure Blood and Urine test (Liver, Kidney function, lipid, UA) Characteristics of patients who well responded to SGLT2 inhibitors Comparison of eGFR decline change with that in non-SGLT2 inhibitors users who were matched background	—

Countries

Japan

Contacts

Public ContactYoshio Kurihara

Kurihara Naika Clinic Internal Medicine

ykuri@yg7.so-net.ne.jp011-892-3522

Outcome results